Guiding multi-modal therapies against minimal residual disease by liquid biopsies
Conditions: Pancreatic Adenocarcinoma Interventions: Diagnostic Test: liquid biopsy Sponsors: Karolinska University Hospital; Universit ätsklinikum Hamburg-Eppendorf; Aarhus University Hospital; Centre Hospitalier Universitaire de Nice; Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III; Medical University of Graz; Centre Hospitalier Régional Universitaire Montpellier Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Conditions: Metastatic Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8 Interventions: Drug: BET Bromodomain Inhibitor ZEN-3694; Procedure: Biopsy; Procedure: Biospecimen Collection; Biological: Cetuximab; Procedure: Computed Tomography; Drug: Encorafenib; Procedure: Magnetic Resonance Imaging Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 26, 2023 Category: Research Source Type: clinical trials
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
Conditions: Pancreatic Adenocarcinoma; Homologous Recombination Deficiency Interventions: Drug: Cisplatin Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 23, 2023 Category: Research Source Type: clinical trials
Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Conditions: Gastric Cancer; Gastroesophageal-junction Cancer; Advanced Cancer Interventions: Drug: TST001, CapOx or mFOLFOX6 and NIVO or (Substudy) TST001, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU); Drug: Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU) Sponsors: Suzhou Transcenta Therapeutics Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma
Conditions: Bile Duct Adenocarcinoma Interventions: Drug: surufatinib plus cadonilimab Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 20, 2023 Category: Research Source Type: clinical trials
Liquid Biopsy for the Diagnosis of Intestinal-type Adenocarcinoma of the Ethmoid (BLADE)
Conditions: Ethmoid Sinus Tumor; Adenocarcinoma; Circulating Tumor Cell Interventions: Diagnostic Test: Liquid biopsy Sponsors: University Hospital, Montpellier; GEFLUC Occitanie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer
Conditions: Stage III Pancreatic Cancer American Joint Committee on Cancer (AJCC) v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma Interventions: Other: Best Practice; Other: Dietary Intervention; Other: Medical Chart Review; Other: Medical Device Usage and Evaluation; Other: Nutritional Assessment; Other: Questionnaire Administration Sponsors: Jonsson Comprehensive Cancer Center; Silicon Valley Community Foundation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
XELOX Combined With Fruquintinib and Sintilimab Regimen Conversion Therapy for Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Only With Liver and/or Retroperitoneal Lymph Node Metastasis, a Prospective Single-arm, Multicenter Study
Conditions: Gastric Cancer/Gastroesophageal Junction Adenocarcinoma Interventions: Drug: XELOX combined with Fruquintinib and Sintilimab Sponsors: Xiaofeng Chen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
Conditions: Advanced Solid Tumor; CDKN2A; NSCLC; Urothelial Carcinoma Bladder; Melanoma; Pancreas Adenocarcinoma; HNSCC; Renal Cell Carcinoma; Mesothelioma; Gastric Cancer Interventions: Drug: Milademetan; Drug: Atezolizumab Sponsors: Rain Oncology Inc Withdrawn (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 19, 2023 Category: Research Source Type: clinical trials
Association Between Tumor Size and Prognosis in Patients With Small Bowel adenocarcinoma-a SEER-based Study
Conditions: Prognosis Interventions: Other: no interventions Sponsors: Zhe Fan Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 18, 2023 Category: Research Source Type: clinical trials
A Study of Sovilnesib in Subjects With Ovarian Cancer
Conditions: High Grade Serous Adenocarcinoma of Ovary; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Chromosomal Instability Interventions: Drug: Sovilnesib Sponsors: Volastra Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
A Phase Ib Study of Sovilnesib in Subjects With Ovarian Cancer
Conditions: High Grade Serous Adenocarcinoma of Ovary; Fallopian Tube Cancer; Primary Peritoneal Carcinoma; Chromosomal Instability Interventions: Drug: Sovilnesib Sponsors: Volastra Therapeutics, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Metastatic Left Colon and Rectal Cancer Treatment With Anti_EGFR Targeted Therapy
Conditions: Metastatic Colorectal Adenocarcinoma Sponsors: Assiut University Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Conditions: Hepatocellular Carcinoma; Pancreatic Ductal Adenocarcinoma; Biliary Tract Cancers; Esophageal Squamous Cell Carcinoma; Triple Negative Breast Cancer; Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer; Head and Neck Squamous-Cell Carcinoma Interventions: Drug: ABBV-400 Sponsors: AbbVie Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 16, 2023 Category: Research Source Type: clinical trials
A Study of OT-101 With FOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
Conditions: Pancreatic Ductal Adenocarcinoma Interventions: Drug: OT-101; Drug: FOLFIRINOX Sponsors: Oncotelic Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
